鼻茸を伴わない慢性副鼻腔炎（CRSsNP） - 市場考察、疫学、市場予測（2032年）

主なハイライト

• 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）市場は、予測期間（2023年～2032年）を通して安定した成長が見込まれています。鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場規模は、人口の増加と診断の向上により、主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）で拡大すると予測されます。
• 主要7市場において、市場は主に標準治療で構成され、2022年に約39億米ドルを創出しました。
• 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）治療市場の総市場規模は、LYR-210、XHANCE（OPN-375）、LYR-220などの新しく効果的な治療薬の出現により、予測期間中に成長が見込まれます。

鼻茸を伴わない慢性副鼻腔炎（CRSsNP）市場の見通し

抗生物質と副腎皮質ステロイドは、現在の治療情勢における主な収益源です。抗生物質と副腎皮質ステロイド（経鼻、経口）の使用は、CRSsNPを管理するために医療従事者にエビデンスに基づく助言を提供する臨床診療ガイドラインによって指導されています。

鼻茸を伴わない慢性副鼻腔炎（CRSsNP）市場は、LYR-210、OPN-375/XHANCE, LYR-220のような潜在的な薬剤の承認により、プラス成長が予測されます。

当レポートでは、鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）市場の概要：国別

• 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場シェア分布：国別（2019年）
• 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場シェア分布：国別（2032年）

第4章 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）市場の概要：治療法別

• 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場シェア分布：治療法別（2019年）
• 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場シェア分布：治療法別（2032年）

第5章 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の調査手法の疫学と市場

第6章 鼻茸を伴わない慢性副鼻腔炎（CRSsNP）のエグゼクティブサマリー

第7章 主な出来事

第8章 疾患の背景と概要：CRSsNP

• イントロダクション
• 表現型とエンドタイプ
• 遺伝学
• 病因
• 病態生理学
• 兆候と症状
• 診断
  • 診断基準
  • 診断アルゴリズム
• 治療と管理
  • 治療アルゴリズム
  • 治療ガイドライン

第9章 疫学と患者数

• 主な調査結果
• 前提条件と根拠：主要7市場
  • 米国
  • 欧州4ヶ国（ドイツ、フランス、イタリア、スペイン）・英国
  • 日本
• 主要7市場のCRSと診断された症例の総数
• 主要7市場の鼻茸を伴わない慢性副鼻腔炎（CRSsNP）と診断された症例の総数
• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第10章 ペイシェントジャーニー

第11章 新薬

• 主な競合
• XHANCE (fluticasone propionate)/OPN-375: Optinose US Inc.
• LYR-210: Lyra Therapeutics
• LYR-220: Lyra Therapeutics
• Brensocatib: Insmed, Inc. DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals

第12章 CRSsNP：市場の分析

• 主な調査結果
• 主な市場予測の前提条件
• 市場見通し
• コンジョイント分析
• 主要7市場の鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場規模
• 主要7市場の鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場規模：治療法別
• 米国の市場規模
  • 米国の鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の総市場規模
  • 米国の鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本の市場規模
  • 日本の鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場規模
  • 日本の鼻茸を伴わない慢性副鼻腔炎（CRSsNP）の市場規模：治療法別

第13章 主なオピニオンリーダーの見解

第14章 SWOT分析

第15章 アンメットニーズ

第16章 市場参入と償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本

第17章 付録

第18章 レポート調査手法

第19章 DelveInsightのサービス内容

第20章 免責事項

List of Tables

• Table 1: Summary of Chronic Rhinosinusitis Without Nasal Polyps Market and Epidemiology (2019-2032)
• Table 2: Key Events
• Table 3: JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis
• Table 4: Key EPOS Treatment Recommendations and Supporting Evidence
• Table 5: Grade A/B Evidence-based Recommendations for Medical Management of CRSsNP
• Table 6: Total Diagnosed Prevalent Cases of CRS in the 7MM (2019-2032)
• Table 7: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM (2019-2032)
• Table 8: Total Prevalent Cases of CRS in the US (2019-2032)
• Table 9: Total Diagnosed Prevalent Cases of CRS in the US (2019-2032)
• Table 10: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the US (2019-2032)
• Table 11: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the US (2019-2032)
• Table 12: Total Prevalent Cases of CRS in Germany (2019-2032)
• Table 13: Total Diagnosed Prevalent Cases of CRS in Germany (2019-2032)
• Table 14: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Germany (2019-2032)
• Table 15: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Germany (2019-2032)
• Table 16: Total Prevalent Cases of CRS in France (2019-2032)
• Table 17: Total Diagnosed Prevalent Cases of CRS in France (2019-2032)
• Table 18: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in France (2019-2032)
• Table 19: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in France (2019-2032)
• Table 20: Total Prevalent Cases of CRS in Italy (2019-2032)
• Table 21: Total Diagnosed Prevalent Cases of CRS in Italy (2019-2032)
• Table 22: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Italy (2019-2032)
• Table 23: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Italy (2019-2032)
• Table 24: Total Prevalent Cases of CRS in Spain (2019-2032)
• Table 25: Total Diagnosed Prevalent Cases of CRS in Spain (2019-2032)
• Table 26: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Spain (2019-2032)
• Table 27: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Spain (2019-2032)
• Table 28: Total Prevalent Cases of CRS in the UK (2019-2032)
• Table 29: Total Diagnosed Prevalent Cases of CRS in the UK (2019-2032)
• Table 30: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the UK (2019-2032)
• Table 31: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the UK (2019-2032)
• Table 32: Total Prevalent Cases of CRS in EU4 and the UK (2019-2032)
• Table 33: Total Diagnosed Prevalent Cases of CRS in EU4 and the UK (2019-2032)
• Table 34: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in EU4 and the UK (2019-2032)
• Table 35: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in EU4 and the UK (2019-2032)
• Table 36: Total Prevalent Cases of CRS in Japan (2019-2032)
• Table 37: Total Diagnosed Prevalent Cases of CRS in Japan (2019-2032)
• Table 38: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Japan (2019-2032)
• Table 39: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Japan (2019-2032)
• Table 40: Comparison of Emerging Drugs Under Development
• Table 41: OPN-375, Clinical Trial Description, 2023
• Table 42: LYR-210, Clinical Trial Description, 2023
• Table 43: LYR-220, Clinical Trial Description, 2023
• Table 44: Dupilumab, Clinical Trial Description, 2023
• Table 45: Key Market Forecast Assumptions for XHANCE (OPN-375)
• Table 46: Key Market Forecast Assumptions for LYR-210
• Table 47: Key Market Forecast Assumptions for LYR-220
• Table 48: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM
• Table 49: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in the 7MM
• Table 50: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the US
• Table 51: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in the US
• Table 52: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Germany
• Table 53: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in France
• Table 54: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Italy
• Table 55: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Spain
• Table 56: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the UK
• Table 57: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in EU4 and the UK
• Table 58: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Germany
• Table 59: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in France
• Table 60: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Italy
• Table 61: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Spain
• Table 62: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in the UK
• Table 63: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in EU4 and the UK
• Table 64: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Japan
• Table 65: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Japan

List of Figures

• Figure 1: Location of Paranasal Sinuses
• Figure 2: Subtypes of CRS Based on the Presence of Nasal Polyps
• Figure 3: Schematic Depiction of Pathological Mechanisms of CRSsNP
• Figure 4: Symptoms of CRSsNP
• Figure 5: Diagnostic Algorithm of Refractory Chronic Rhinosinusitis
• Figure 6: Diagnosis Algorithm of CRSsNP
• Figure 7: Treatment Algorithm for CRSsNP
• Figure 8: CRS Clinical Presentation
• Figure 9: Total Diagnosed Prevalent Cases of CRS in the 7MM (2019-2032)
• Figure 10: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM (2019-2032)
• Figure 11: Total Prevalent Cases of CRS in the United States (2019-2032)
• Figure 12: Total Diagnosed Prevalent Cases of CRS in the US (2019-2032)
• Figure 13: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the US (2019-2032)
• Figure 14: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the US (2019-2032)
• Figure 15: Total Prevalent Cases of CRS in Germany (2019-2032)
• Figure 16: Total Diagnosed Prevalent Cases of CRS in Germany (2019-2032)
• Figure 17: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Germany (2019-2032)
• Figure 18: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Germany (2019-2032)
• Figure 19: Total Prevalent Cases of CRS in France (2019-2032)
• Figure 20: Total Diagnosed Prevalent Cases of CRS in France (2019-2032)
• Figure 21: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in France (2019-2032)
• Figure 22: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in France (2019-2032)
• Figure 23: Total Prevalent Cases of CRS in Italy (2019-2032)
• Figure 24: Total Diagnosed Prevalent Cases of CRS in Italy (2019-2032)
• Figure 25: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Italy (2019-2032)
• Figure 26: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Italy (2019-2032)
• Figure 27: Total Prevalent Cases of CRS in Spain (2019-2032)
• Figure 28: Total Diagnosed Prevalent Cases of CRS in Spain (2019-2032)
• Figure 29: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Spain (2019-2032)
• Figure 30: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Spain (2019-2032)
• Figure 31: Total Prevalent Cases of CRS in the UK (2019-2032)
• Figure 32: Total Diagnosed Prevalent Cases of CRS in the UK (2019-2032)
• Figure 33: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the UK (2019-2032)
• Figure 34: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the UK (2019-2032)
• Figure 35: Prevalent Cases of CRS in EU4 and the UK (2019-2032)
• Figure 36: Total Diagnosed Prevalent Cases of CRS in EU4 and the UK (2019-2032)
• Figure 37: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in EU4 and the UK (2019-2032)
• Figure 38: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in EU4 and the UK (2019-2032)
• Figure 39: Total Prevalent Cases of CRS in Japan (2019-2032)
• Figure 40: Total Diagnosed Prevalent Cases of CRS in Japan (2019-2032)
• Figure 41: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Japan (2019-2032)
• Figure 42: Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Japan (2019-2032)
• Figure 43: Patient Journey of CRSsNP
• Figure 44: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM
• Figure 45: Market Size by Therapy of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM
• Figure 46: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the US
• Figure 47: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in the US
• Figure 48: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Germany
• Figure 49: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in France
• Figure 50: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Italy
• Figure 51: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Spain
• Figure 52: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the UK
• Figure 53: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in EU4 and the UK
• Figure 54: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Germany
• Figure 55: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in France
• Figure 56: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Italy
• Figure 57: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Spain
• Figure 58: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in the UK
• Figure 59: Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in EU4 and the UK
• Figure 60: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Japan
• Figure 61: Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Japan
• Figure 62: Unmet Needs
• Figure 63: Health Technology Assessment
• Figure 64: Reimbursement Process in Germany
• Figure 65: Reimbursement Process in France
• Figure 66: Reimbursement Process in Spain
• Figure 67: Reimbursement Process in the United Kingdom
• Figure 68: Reimbursement Process in Japan

Key Highlights:

• The Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) market is projected to witness consistent growth throughout the forecast period (2023-2032). The market size of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM is expected to increase, driven by an increase in the population and better diagnosis.
• DelveInsight's analyst projects that approximately 81% of individuals diagnosed with CRS belong to the Chronic Rhinosinusitis Without Nasal Polyps category in the US. As per our estimations, in 2022, the US accounted for 8.8 million diagnosed prevalent cases of CRSsNP.
• As per DelveInsight's analysis, EU4 and the UK comprised around 42% of the diagnosed prevalent cases of Chronic Rhinosinusitis Without Nasal Polyps in 2022 among the 7MM.
• Japan accounted for more than 1.1 million diagnosed prevalent cases of Chronic Rhinosinusitis Without Nasal Polyps in 2022.
• In the 7MM, the market mainly consisted of standard of care, which generated nearly USD 3.9 billion in 2022.
• The total market size of the Chronic Rhinosinusitis Without Nasal Polyps treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, LYR-210, XHANCE (OPN-375), and LYR-220, among others.

DelveInsight's "Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the CRSsNP, historical and forecasted epidemiology and the chronic rhinosinusitis without nasal polyps market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The chronic rhinosinusitis without nasal polyps market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM chronic rhinosinusitis without nasal polyps market size from 2019 to 2032. The report also covers current chronic rhinosinusitis without nasal polyps treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032.

Disease Understanding and Treatment Algorithm

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Overview

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is a prevalent and chronic medical condition characterized by inflammation and swelling of the nasal passages and paranasal sinuses, but notably, it does not involve the presence of nasal polyps.

Individuals with chronic rhinosinusitis without nasal polyps often experience symptoms such as nasal congestion, difficulty breathing through the nose, facial pain or pressure, reduced sense of smell (hyposmia), and a persistent discharge from the nose. These symptoms typically last more than 12 weeks, making it a chronic condition requiring proper management.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Diagnosis

Diagnosing chronic rhinosinusitis without nasal polyps involves a thorough examination of the nasal passages and sinuses by medical professionals, who may also consider the patient's medical history and the duration of symptoms to differentiate it from other similar conditions. The diagnosis is typically based on specific diagnostic criteria established by medical guidelines. These criteria include two or more of the following major symptoms: nasal blockage/congestion, nasal discharge, facial pain/pressure, and reduced sense of smell. The symptoms of CRSsNP must be present for at least 12 consecutive weeks to meet the diagnosis. In some cases, the doctor may order imaging studies, such as a CT scan of the sinuses.

Further details related to country-based variations are provided in the report.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Treatment

Treatment for chronic rhinosinusitis without nasal polyps alleviates inflammation and effectively manages symptoms. Medical management may include the use of nasal corticosteroids to reduce inflammation and antibiotics if there is evidence of a bacterial infection. Nasal irrigations or rinses with saline solutions may also be recommended to help improve nasal health and provide relief. If medical treatment fails to provide sufficient symptom relief or disease control, surgical interventions such as endoscopic sinus surgery (ESS) may be considered.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Epidemiology

As the market is derived using the patient-based model, the chronic rhinosinusitis without nasal polyps epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Chronic Rhinosinusitis, Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis, Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), and Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032. As per DelveInsight's estimations, the total diagnosed prevalent cases of chronic rhinosinusitis without nasal polyps in the 7MM was approximately 17 million cases in 2022 and are projected to increase during the forecast period.

• In 2022, among the 7MM, the US recorded the highest number of prevalent cases of Chronic Rhinosinusitis (CRS), with approximately 31 million cases. Across all the 7MM countries, the total number of prevalent CRS cases was approximately 71 million, and these cases are projected to increase by 2032.
• In 2022, there were an estimated 9 million diagnosed cases of CRS out of a total of 31 million prevalent cases in EU4 and the UK.
• DelveInsight's analysis indicates that approximately 81% of the total diagnosed cases of CRS in the 7MM were diagnosed as chronic rhinosinusitis without nasal polyps accounting for about 17 million cases in the 7MM, among which the US accounted for 51% of the cases.
• The assessment indicates that the number of chronic rhinosinusitis without nasal polyps cases in Japan is projected to decrease at a significant CAGR during the forecast period (2023-2032) due to a declining population.
• The United States has the highest number of diagnosed cases of chronic rhinosinusitis without nasal polyps in females compared to males. In 2022, of all chronic rhinosinusitis without nasal polyps cases, approximately 63% were females, while around 37% of males were diagnosed with the condition.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Drug Chapters

The drug chapter segment of the chronic rhinosinusitis without nasal polyps report encloses a detailed analysis of chronic rhinosinusitis without nasal polyps marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands chronic rhinosinusitis without nasal polyps clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs:

XHANCE (fluticasone propionate)/OPN-375: Optinose US Inc.

Optinose US Inc.'s first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 µg, is therapeutic, utilizing a proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and if approved, chronic rhinosinusitis without nasal polyps. In September 2017, the US FDA approved XHANCE for treating nasal polyps in patients aged 18 or older, and it was made widely available through commercial channels in April 2018. This product candidate is currently in Phase III of its clinical development for CRSsNP.

LYR-210: Lyra Therapeutics

LYR-210 is an anti-inflammatory implantable drug matrix designed to consistently and locally elute mometasone furoate, or MF, to the inflamed mucosal tissue for up to 6 months in surgically naive CRS patients with and without nasal polyps who have failed previous medical management. LYR-210 is undergoing a Phase III program, the ENLIGHTEN, comprising two pivotal trials. These trials are currently in progress and are crucial in determining the drug's efficacy and safety. Both trials will enroll surgically naive CRS patients in the US and Europe to support the company's FDA submission.

Note: Detailed emerging therapies assessment will be provided in the final report of CRSsNP.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market Outlook

Chronic Rhinosinusitis Without Nasal Polyps has a diverse treatment classification associated with the disease landscape. The primary goal of treatment for chronic rhinosinusitis without nasal polyps is to reduce inflammation, control symptoms, and improve the patient's quality of life.

Antibiotics and corticosteroids are major revenue generators in the current treatment landscape. The use of antibiotics and corticosteroids (intranasal and oral) is guided by clinical practice guidelines, which provide evidence-based recommendations to healthcare professionals to manage CRSsNP.

The market for chronic rhinosinusitis without nasal polyps is expected to experience positive growth with the approval of potential drugs like LYR-210, OPN-375/ XHANCE, and LYR-220.

• The Chronic Rhinosinusitis with Nasal Polyps (CRSsNP) market's total size in the 7MM reached approximately USD 3.9 billion in 2022. Projections indicate a substantial CAGR from 2022 to 2032.
• Out of the 7MM, the United States dominated the market in 2022, representing the largest share at 64%.
• In 2022, EU4 and the UK captured nearly 31% and Japan around 5% of the total market share in the 7MM.
• Among the forecasted emerging therapies, LYR-210 is expected to capture the highest market in the 7MM by 2032.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, LYR-210 in the US is expected to have medium-fast drug uptake with a probability-adjusted peak share of around 12%, and years to the peak is expected to be 6 years from the year of launch.

Further detailed analysis of emerging therapies drug uptake in the report…

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for chronic rhinosinusitis without nasal polyps emerging therapies.

KOL Views:

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on chronic rhinosinusitis without nasal polyps evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Department of Surgery, Ralph H. Johnson VA Medical Center; Department of Otorhinolaryngology, Ulm University Medical Center, Frauensteige; Department of Allergy and Medical Rhinology, University College London, London; Department of Pediatrics, Nippon Medical School, Tokyo, and others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or chronic rhinosinusitis without nasal polyps market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help shape and drive the 7MM Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) market.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Report Insights

• Patient Population
• Therapeutic Approaches
• Chronic Rhinosinusitis Without Nasal Polyps Pipeline Analysis
• Chronic Rhinosinusitis Without Nasal Polyps Market Size and Trends
• Existing and Future Market Opportunity

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Chronic Rhinosinusitis Without Nasal Polyps Epidemiology Segmentation
• Key Cross Competition
• Attribute Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) total market size, the market size by therapies, and market share (%) distribution in 2019, and how would it all look in 2032? What are the contributing factors for this growth?
• What unmet needs are associated with the current treatment market of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• What will be the impact of the XHANCE patent expiry in the market?
• How will XHANCE compete with the existing therapies for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) during the study period?
• Which drug is going to be the largest contributor in 2032?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)? What will be the growth opportunities across the 7MM concerning the patient population of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• What is the historical and forecasted Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which type of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) is more prevalent and why?
• What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)? What are the current guidelines for treating Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) in the US and Europe?
• How many companies are developing therapies for treating Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• How many emerging therapies are in the mid-stage and late stage of development for treating Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the key designations that have been granted for the emerging therapies for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted markets of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Country-wise Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market Overview at a Glance

• 3.1. Country-wise Market Share (%) Distribution of Chronic Rhinosinusitis Without Nasal Polyps in 2019
• 3.2. Country-wise Market Share (%) Distribution of Chronic Rhinosinusitis Without Nasal Polyps in 2032

4. Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) Market Overview by Therapies

• 4.1. Market Share (%) Distribution of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in 2019
• 4.2. Market Share (%) Distribution of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in 2032

5. Methodology of Chronic Rhinosinusitis Without Nasal Polyps Epidemiology and Market

6. Executive Summary of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

7. Key Events

8. Disease Background and Overview: CRSsNP

• 8.1. Introduction
• 8.2. Phenotypes and Endotypes
• 8.3. Genetics
• 8.4. Pathogenesis
• 8.5. Pathophysiology
• 8.6. Signs and Symptoms
• 8.7. Diagnosis
  • 8.7.1. Diagnosis Criteria
    • 8.7.1.1. EUFOREA Rhinology Research Forum 2016
    • 8.7.1.2. JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis (ECRS)
  • 8.7.2. Diagnostic Algorithm
• 8.8. Treatment and Management
  • 8.8.1. Treatment Algorithm
  • 8.8.2. Treatment Guidelines
    • 8.8.2.1. EPOS Primary Care Guidelines
    • 8.8.2.2. International Consensus Statement on Rhinology and Allergy: Rhinosinusitis

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. The United States
  • 9.2.2. EU4 (Germany, France, Italy, Spain) and the United Kingdom
  • 9.2.3. Japan
• 9.3. Total Diagnosed Prevalent Cases of CRS in the 7MM
• 9.4. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM
• 9.5. The United States
  • 9.5.1. Total Prevalent Cases of CRS in the US
  • 9.5.2. Total Diagnosed Prevalent Cases of CRS in the US
  • 9.5.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the US
  • 9.5.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the US
• 9.6. EU4 and the UK
  • 9.6.1. Germany
    • 9.6.1.1. Total Prevalent Cases of CRS in Germany
    • 9.6.1.2. Total Diagnosed Prevalent Cases of CRS in Germany
    • 9.6.1.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Germany
    • 9.6.1.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Germany
  • 9.6.2. France
    • 9.6.2.1. Total Prevalent Cases of CRS in France
    • 9.6.2.2. Total Diagnosed Prevalent Cases of CRS in France
    • 9.6.2.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in France
    • 9.6.2.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in France
  • 9.6.3. Italy
    • 9.6.3.1. Total Prevalent Cases of CRS in Italy
    • 9.6.3.2. Total Diagnosed Prevalent Cases of CRS in Italy
    • 9.6.3.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Italy
    • 9.6.3.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Italy
  • 9.6.4. Spain
    • 9.6.4.1. Total Prevalent Cases of CRS in Spain
    • 9.6.4.2. Total Diagnosed Prevalent Cases of CRS in Spain
    • 9.6.4.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Spain
    • 9.6.4.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Spain
  • 9.6.5. The UK
    • 9.6.5.1. Total Prevalent Cases of CRS in the UK
    • 9.6.5.2. Total Diagnosed Prevalent Cases of CRS in the UK
    • 9.6.5.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the UK
    • 9.6.5.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in the UK
• 9.7. Japan
  • 9.7.1. Total Prevalent Cases of CRS in Japan
  • 9.7.2. Total Diagnosed Prevalent Cases of CRS in Japan
  • 9.7.3. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Japan
  • 9.7.4. Gender-specific Diagnosed Prevalent Cases of Chronic Rhinosinusitis Without Nasal Polyps in Japan

10. Patient Journey

11. Emerging Drugs

• 11.1. Key Cross Competition
• 11.2. XHANCE (fluticasone propionate)/OPN-375: Optinose US Inc.
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activity
  • 11.2.3. Clinical Development
  • 11.2.4. Clinical Trials Information
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Product Profile
  • 11.2.7. Analysts' Views
• 11.3. LYR-210: Lyra Therapeutics
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activity
  • 11.3.3. Clinical Development
  • 11.3.4. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Product Profile
  • 11.3.7. Analysts' Views
• 11.4. LYR-220: Lyra Therapeutics
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activity
  • 11.4.3. Clinical Development
  • 11.4.4. Clinical Trials Information
  • 11.4.5. Safety and Efficacy
  • 11.4.6. Product Profile
  • 11.4.7. Analysts' Views
• 11.5. Brensocatib: Insmed, Inc. DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
  • 11.5.1. Product Description
  • 11.5.2. Other Developmental Activity
  • 11.5.3. Clinical Development
  • 11.5.4. Clinical Trials Information
  • 11.5.5. Product Profile
  • 11.5.6. Analysts' Views
• . Detailed list to be provided in the report.

12. CRSsNP: Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
• 12.3. Market Outlook
• 12.4. Conjoint Analysis
• 12.5. Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM
• 12.6. Market Size by Therapies of Chronic Rhinosinusitis Without Nasal Polyps in the 7MM
• 12.7. The United States Market Size
  • 12.7.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the United States
  • 12.7.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in the United States
• 12.8. EU4 and the UK Market Size
  • 12.8.1. Germany
    • 12.8.1.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Germany
    • 12.8.1.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Germany
  • 12.8.2. France
    • 12.8.2.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in France
    • 12.8.2.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in France
  • 12.8.3. Italy
    • 12.8.3.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Italy
    • 12.8.3.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Italy
  • 12.8.4. Spain
    • 12.8.4.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Spain
    • 12.8.4.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Spain
  • 12.8.5. The UK
    • 12.8.5.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in the UK
    • 12.8.5.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in the UK
• 12.9. Japan Market Size
  • 12.9.1. Total Market Size of Chronic Rhinosinusitis Without Nasal Polyps in Japan
  • 12.9.2. Market Size of Chronic Rhinosinusitis Without Nasal Polyps by Therapies in Japan

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Center for Medicare & Medicaid Services (CMS)
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations

18. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer